DF/HCC Program Affiliation

Cancer Imaging

Research Abstract

Our laboratory is engaged in the development of transition-metal based radiopharmaceuticals for cancer imaging and therapy. The focus of the imaging program is on the development of Cu-64-based PET agents that can be used to non-invasively evaluate the multidrug resistance status of patients with breast and other types of cancer. These new copper complexes are, like the MDR chemotherapeutics, substrates for Pgp, the protein implicated in MDR1 multidrug resistance. We are also developing new antibody/chelate conjugates for use in attaching Cu-64 (and other diagnostic and therapeutic radionuclides) to engineered antibody fragments. In collaboration with Mark Kieran (DFCI), we are evaluating new imaging agents targeted to the vitronectin receptor for directly monitoring clinical response to anti-angiogenesis therapy.

Publications

View All Publications